1
Home
Companies

Codexis

#8784

Rank

$159.87M

Marketcap

US United States

Country

Codexis
Leadership team

Dr. Stephen George Dilly MBBS, Ph.D. (Pres, CEO & Director)

Mr. Ross Taylor Jr., M.B.A. (Sr. VP & CFO)

Mr. John J. Nicols (Director & Strategic Advisor)

Products/ Services
Biotechnology, Chemical, Sustainability
Number of Employees
100 - 500
Headquarters
Redwood City, California, United States
Established
2002
Company Registration
SEC CIK number: 0001200375
Revenue
100M - 500M
Traded as
CDXS
Social Media
URL
https://www.codexis.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
History

Codexis is based in Redwood City, CA and was incorporated in 2002. It went public in April 2010 on NASDAQ, and in October, acquired Maxygen's MolecularBreeding technology portfolio.

Pharmaceutical

Codexis won the Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency in 2006 for its work on a building block of Lipitor. It then won a second time in 2010 for its work with Merck & Co. on the active ingredient in Januvia.

Nutrition

In 2017, the company entered a partnership with Tate & Lyle to provide research and development for the production of new ingredients. That same year, Codexis announced a collaboration with Nestle to provide enzymes for metabolic disorders.

Biotherapeutics

In 2017, Codexis developed a recombinant phenylalanine ammonia-lyase enzyme, to act as a substitute phenylalanine hydroxylase enzyme for people who suffer from phenylketonuria. The enzyme was in-licensed by Nestle Health Sciences.In 2020, Takeda Pharmaceutical announced a collaboration with Codexis to research and create gene therapies for rare diseases, including lysosomal storage disorders.

Life science

In June 2020, they announced a partnership with Molecular Assemblies to engineer enzymes for DNA synthesis.

Mission
Our mission is to drive innovation through the engineering of proteins, advancing solutions in biomanufacturing, therapeutics, and innovative solutions that improve the way we live.
Vision
Our vision is to create a healthier, more sustainable future through protein engineering, empowering biomanufacturing and therapeutic solutions that improve human health and well-being.
Key Team

Mr. Kevin Norrett M.B.A., M.S. (Chief Operating Officer)

Ms. Margaret Fitzgerald J.D. (Chief Legal and Compliance Officer, Gen. Counsel & Sec.)

Ms. Asli Aras Ph.D. (VP & Head of Corp. Devel.)

Ms. Karen Frechou-Armijo (Sr. VP & Head of HR)

Mr. Rob Wilson Ph.D. (Sr. VP & GM of Performance Enzymes)

Dr. Karl A. Schoene Ph.D. (Sr. VP of Devel. & Operations)

Dr. Stefan Lutz Ph.D. (Sr. VP of Research)

Recognition and Awards
Codexis has been recognized for numerous awards and honors, including the MIT Technology Review TR35, Global Cleantech 100 Award, U.S. Department of Energy Technology and Innovation Award, Bloomberg New Energy Pioneer, and the Cradle to Cradle Innovation Award for Sustainable Protein Production.
References

https://en.wikipedia.org/wiki/Codexis

https://in.investing.com/equities/codexis

https://finance.yahoo.com/quote/CDXS/profile?p=CDXS

https://www.crunchbase.com/organization/codexis

https://companiesmarketcap.com/

https://www.codexis.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Codexis
Leadership team

Dr. Stephen George Dilly MBBS, Ph.D. (Pres, CEO & Director)

Mr. Ross Taylor Jr., M.B.A. (Sr. VP & CFO)

Mr. John J. Nicols (Director & Strategic Advisor)

Products/ Services
Biotechnology, Chemical, Sustainability
Number of Employees
100 - 500
Headquarters
Redwood City, California, United States
Established
2002
Company Registration
SEC CIK number: 0001200375
Revenue
100M - 500M
Traded as
CDXS
Social Media
URL
https://www.codexis.com